Tags

Type your tag names separated by a space and hit enter

Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives.
Eur J Med Chem. 2017 Dec 15; 142:8-31.EJ

Abstract

Metallodrugs offer potential for unique mechanism of drug action based on the choice of the metal, its oxidation state, the types and number of coordinated ligands and the coordination geometry. This review illustrates notable recent progress in the field of medicinal bioinorganic chemistry as many new approaches to the design of innovative metal-based anticancer drugs are emerging. Current research addressing the problems associated with platinum drugs has focused on other metal-based therapeutics that have different modes of action and on prodrug and targeting strategies in an effort to diminish the side-effects of cisplatin chemotherapy. Examples of metal compounds and chelating agents currently in clinical use, clinical trials or preclinical development are highlighted.

Authors+Show Affiliations

University of Kragujevac, Faculty of Medicine, S. Marković 69, 34000, Kragujevac, Serbia.University of Kragujevac, Faculty of Science, R. Domanovića 12, P. O. Box 60, 34000 Kragujevac, Serbia. Electronic address: anarilak@kg.ac.rs.University of Kragujevac, Faculty of Science, R. Domanovića 12, P. O. Box 60, 34000 Kragujevac, Serbia. Electronic address: bugarcic@kg.ac.rs.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

28442170

Citation

Lazarević, Tatjana, et al. "Platinum, Palladium, Gold and Ruthenium Complexes as Anticancer Agents: Current Clinical Uses, Cytotoxicity Studies and Future Perspectives." European Journal of Medicinal Chemistry, vol. 142, 2017, pp. 8-31.
Lazarević T, Rilak A, Bugarčić ŽD. Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives. Eur J Med Chem. 2017;142:8-31.
Lazarević, T., Rilak, A., & Bugarčić, Ž. D. (2017). Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives. European Journal of Medicinal Chemistry, 142, 8-31. https://doi.org/10.1016/j.ejmech.2017.04.007
Lazarević T, Rilak A, Bugarčić ŽD. Platinum, Palladium, Gold and Ruthenium Complexes as Anticancer Agents: Current Clinical Uses, Cytotoxicity Studies and Future Perspectives. Eur J Med Chem. 2017 Dec 15;142:8-31. PubMed PMID: 28442170.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives. AU - Lazarević,Tatjana, AU - Rilak,Ana, AU - Bugarčić,Živadin D, Y1 - 2017/04/18/ PY - 2017/01/31/received PY - 2017/03/30/revised PY - 2017/04/03/accepted PY - 2017/4/27/pubmed PY - 2017/12/13/medline PY - 2017/4/27/entrez KW - Anticancer agents KW - Cytotoxicity KW - DNA KW - Proteins SP - 8 EP - 31 JF - European journal of medicinal chemistry JO - Eur J Med Chem VL - 142 N2 - Metallodrugs offer potential for unique mechanism of drug action based on the choice of the metal, its oxidation state, the types and number of coordinated ligands and the coordination geometry. This review illustrates notable recent progress in the field of medicinal bioinorganic chemistry as many new approaches to the design of innovative metal-based anticancer drugs are emerging. Current research addressing the problems associated with platinum drugs has focused on other metal-based therapeutics that have different modes of action and on prodrug and targeting strategies in an effort to diminish the side-effects of cisplatin chemotherapy. Examples of metal compounds and chelating agents currently in clinical use, clinical trials or preclinical development are highlighted. SN - 1768-3254 UR - https://www.unboundmedicine.com/medline/citation/28442170/Platinum_palladium_gold_and_ruthenium_complexes_as_anticancer_agents:_Current_clinical_uses_cytotoxicity_studies_and_future_perspectives_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0223-5234(17)30262-3 DB - PRIME DP - Unbound Medicine ER -